

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

DISCLOSEABLE TRANSACTION
PURCHASE OF STRUCTURED DEPOSIT

PURCHASE OF STRUCTURED DEPOSIT

The Board announces that on May 5, 2022, the Company entered into the Structured Deposit Agreement XII with SPD Bank, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB540 million from SPD Bank.

LISTING RULES IMPLICATIONS

As all of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules) in respect of the transaction contemplated under the Structured Deposit Agreement XII were below 5%, the purchase of structured deposit under the Structured Deposit Agreement XII does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis. As the Structured Deposit Agreement XII was entered into with the same bank and the transaction thereunder is of a similar nature as the transaction under each of the Structured Deposit Agreement XI and the Structured Deposit Agreement X (which remain outstanding as of the date of this announcement), the transactions contemplated under the Outstanding Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the purchase of structure deposits under the Outstanding Structured Deposit Agreements, on an aggregate basis, exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of structured deposits under the Outstanding Structured Deposit Agreements constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

INTRODUCTION

Reference is made to the announcements of the Company in respect of the purchase of structured deposits from SPD Bank dated February 24, 2022 and February 11, 2022, respectively.

The Board announces that on May 5, 2022, the Company entered into the Structured Deposit Agreement XII with SPD Bank, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB540 million from SPD Bank.

THE STRUCTURED DEPOSIT AGREEMENT XII

The principal terms of the Structured Deposit Agreement XII are set out as follows:

Agreement	Structured Deposit Agreement XII
Date of purchase	May 5, 2022
Parties	(a) The Company; and (b) SPD Bank.
Name of the product	SPD Bank Li Duo Duo Company Stable Profit 22JG6857 (Bullish Three-tier) RMB-denominated Structured Deposit Product* (上海浦東發展銀行利多多公司穩利22JG6857期(三層看漲)人民幣對公結構性存款)
Type of return	Principal-guaranteed with variable return
Purchase amount	RMB540 million The Company is of the view that the consideration of such purchase was determined on the basis of arm's length commercial terms. The structured deposit was purchased with the funds redeemed upon maturity of the structured deposits purchased under the Structured Deposit Agreement VII and the Structured Deposit Agreement IX, without using the H-Share IPO proceeds of the Company.
Term of deposit	From May 6, 2022 to August 4, 2022
Expected annualized floating rate of return	The initial price is the EUR-USD Bloomberg foreign exchange real time rate to be published on the "EUR CURRENCY QR" page of the website of Bloomberg at 10:00 a.m. (Beijing time) on May 9, 2022. The observation price is the EUR-USD Bloomberg foreign exchange real time rate to be published on the "EUR CURRENCY QR" page of the website of Bloomberg at 2:00 p.m. (Beijing time) on August 1, 2022.

The expected annualized floating rate of return will be 0% per annum if the observation price is less than 91.00% of the initial price.

The expected annualized floating rate of return will be 1.75% if the observation price is equal to or higher than 91.00% but less than 103.50% of the initial price.

The expected annualized floating rate of return will be 1.95% if the observation price is equal to or higher than 103.50% of the initial price.

**Principle for
calculation of
return and interest**

Expected return = principal \times (guaranteed return rate (1.35%) + annualized floating rate of return) \times number of days of interest accrual \div 360; actual return is calculated based on simple interest.

Number of days of interest accrual = the number of days during the period from the date of calculation of the return to the expiry date, i.e., the number of whole years \times 360 + the number of whole months \times 30 + the number of days (with beginning date inclusive and end date exclusive).

**Right of early
termination**

The Company has no right of early termination (redemption) for this product.

SPD Bank has the right to early terminate this product according to the actual investment situation without further notice to the customers, provided that it shall publish an information announcement at its branches or websites or in other means within two working days before the date of early termination.

**Payment of principal
and return**

The principal and the return of the product will be paid on the maturity date of the product.

Extension rights

SPD Bank has the right to extend the maturity date of the product according to actual investment situation by publically announcing the extension of maturity date of the product at its branches, on its website or by other ways within two business days prior to the date of maturity of the product without further notice to the customers.

INFORMATION ON THE PARTIES

The Company

The Company is dedicated to exploring best solutions to the prevention of infectious diseases through engaging in research & development, manufacturing and commercialization of high quality vaccine products for human use worldwide.

SPD Bank

SPD Bank is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides corporate and personal banking business, treasury business, finance leasing, asset management and other financial services in the PRC. Its shares are listed on the Shanghai Stock Exchange (stock code: 600000). To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, SPD Bank and its ultimate beneficial owners are parties independent of the Company and its connected persons as of the date of this announcement.

REASONS FOR AND BENEFITS OF THE PURCHASE OF STRUCTURED DEPOSIT

The Company is of the view that the reasonable and efficient use of temporary idle funds will enhance the overall capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The impact of risk factors on the expected rates of return of the Structured Deposit Agreement XII is low, but the Group could get a higher return as compared with fixed term deposit in commercial banks in the PRC.

The Directors consider that the terms of the Structured Deposit Agreement XII and the transaction contemplated thereunder are fair and reasonable, on normal commercial terms or better and in the ordinary course of business of the Group, and are in the interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATIONS

As all of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules) in respect of the transaction contemplated under the Structured Deposit Agreement XII were below 5%, the purchase of structured deposit under the Structured Deposit Agreement XII does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis. As the Structured Deposit Agreement XII was entered into with the same bank and the transaction thereunder is of a similar nature as the transaction under each of the Structured Deposit Agreement XI and the Structured Deposit Agreement X (which remain outstanding as of the date of this announcement), the transactions contemplated under the Outstanding Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the purchase of structure deposits under the Outstanding Structured Deposit Agreements, on an aggregate basis, exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of structured deposits under the Outstanding Structured Deposit Agreements constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

Unless the context otherwise requires, the capitalized terms used herein shall have the following meanings:

“Board”	the board of Directors
“Company”	CanSino Biologics Inc. (康希諾生物股份公司), a joint stock company incorporated in the PRC with limited liability on February 13, 2017, the H Shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 6185) and the A Shares of which are listed on Sci-Tech Innovation Board of the Shanghai Stock Exchange (stock code: 688185)
“connected person”	has the meaning ascribed to it in the Listing Rules
“Directors”	the director(s) of the Company
“EUR”	Euro, the lawful currency of the member states of the European Union
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“H-Share IPO”	initial public offering of the H shares of the Company
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Outstanding Structured Deposit Agreements”	the Structured Deposit Agreement X, the Structured Deposit Agreement XI and the Structured Deposit Agreement XII
“PRC”	the People’s Republic of China, and for the purpose of this announcement only, excluding Hong Kong, the Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“SPD Bank”	Shanghai Pudong Development Bank Co., Ltd., a joint stock company incorporated in the PRC with limited liability and a licensed bank in the PRC, whose shares are listed on the Shanghai Stock Exchange (stock code: 600000)

“Structured Deposit Agreement VII”	the structured deposit agreement entered into between the Company and SPD Bank dated November 11, 2021 in relation to the purchase of structured deposit in the principal amount of RMB700 million
“Structured Deposit Agreement IX”	the structured deposit agreement entered into between the Company and SPD Bank dated January 20, 2022 in relation to the purchase of structured deposit in the principal amount of RMB340 million
“Structured Deposit Agreement X”	the structured deposit agreement entered into between the Company and SPD Bank dated February 11, 2022 in relation to the purchase of structured deposit in the principal amount of RMB500 million
“Structured Deposit Agreement XI”	the structured deposit agreement entered into between the Company and SPD Bank dated February 24, 2022 in relation to the purchase of structured deposit in the principal amount of RMB400 million
“Structured Deposit Agreement XII”	the structured deposit agreement entered into between the Company and SPD Bank dated May 5, 2022 in relation to the purchase of structured deposit in the principal amount of RMB540 million
“USD”	US dollar, the lawful currency of the United States of America
“%”	per cent.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 5, 2022

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.

* *For identification purpose only*